Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions.
The past eighteen months have provided much progress in the cyclic nucleotide phosphodiesterase (PDE) field. Six new phosphodiesterase genes have been discovered and characterized. In addition, several new highly specific PDE inhibitors have been developed and approved for clinical use. Finally, new strategies have been employed to determine PDE function in model systems including the use of antisense oligonucleotide and disruption techniques.
Soderling
S H
SH
Department of Pharmacology, Box 357280, University of Washington, Seattle 98195, USA.
Beavo
J A
JA
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000378:metabolism; D000818:Animals; D000242:Cyclic AMP / Q000378:metabolism*; D006152:Cyclic GMP / Q000378:metabolism*; D005298:Fertility / Q000502:physiology; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D008213:Lymphocyte Activation; D008297:Male; D010410:Penile Erection / Q000502:physiology; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism*; D015398:Signal Transduction; D013601:T-Lymphocytes / Q000276:immunology
D007328:Insulin; D000242:Cyclic AMP; C119843:PDE10A protein, human; D010727:Phosphoric Diester Hydrolases; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D006152:Cyclic GMP